Clarivate acquires analytics solutions provider in life sciences, Bioinfogate

Clarivate has acquired Bioinfogate, a leading provider of analytics solutions in the life sciences and producer of the OFF-X portal. The financial terms of the transaction were not disclosed, as per a statement by Clarivate.

The Bioinfogate OFF-X portal is a cutting-edge safety intelligence solution aimed at empowering pharmaceutical organisations to identify toxicology and safety signals, mitigate safety liabilities and de-risk early-stage assets, the statement said.

It mentioned that the acquisition of Bioinfogate will fill a critical need for drug toxicity data and translational safety intelligence across all stages of drug R&D.

It also said that in combination with Cortellis, OFF-X will provide critical translational safety intelligence alongside robust drug pipeline and clinical research information – allowing biopharma to seamlessly integrate safety intelligence into pre-clinical research, clinical trial planning, regulatory and pharmacovigilance monitoring and portfolio strategy.

Mukhtar Ahmed, President, Science Group, Clarivate, said, “The acquisition of Bioinfogate will further our strategy to become an essential provider of solutions for life science companies along the entire drug development lifecycle. The combined expertise, data and technologies will help customers make smarter and faster evidence-based decisions, boost clinical and commercial success and bolster our robust integrated platform of life science intelligence solutions from pre-clinical and clinical offerings. Ultimately, the acquisition will deepen the end-to-end value chain from R&D through commercialisation and compensation.”

Adding to it, David Prous, Executive Director – Business Development, Bioinfogate, said, “This acquisition will be important to life science firms that need to integrate, access and apply toxicity and adverse events intelligence across all phases of drug research and development. The integration of OFF-X into the Clarivate portfolio of products will further expand and accelerate the reach of critical drug efficacy and safety information to researchers around the world.”